Before you can achieve a high level of operational excellence, you've got to nail down predictability, says Dr. Patrick Yang, Genentech's Executive VP for Products Operations. Too many companies aim high at the start of operational excellence initiatives, Yang says, at the expense of planned, predictable operations.
A large push by Las Vegas economic development authorities to lure biotech companies away from New Jersey, California, and other hotbeds has by and large failed. The promise of tax incentives and cheap land for development means little, it seems, if the local biotech talent pool is dry.
Geez Louise, could the pharma employment picture get much bleaker? On Friday, Schering-Plough announced it would cut 10% of its 55,000 global employees within the next two years, and that the company's Kenilworth, N.J. headquarters would feel the most pain.
Clinical trials may have uncovered a possible link between inhaled insulin and lung cancer. In testing its blockbuster manque Exubera, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer.
The three groups are still disconnected at many drug companies today, as we learned in a very informal survey and touched on in a very brief article recently (click here to read , with insights from Gawayne Mahboubian-Jones (PRODUCT, not Process Development Manager as identified in the article, at Optimal...
This is pretty old news, but it certainly took me by surprise. Just glanced at the online masthead and the byline of an article from the November 2007 issue of Biopharm International and learned that Dr. Hussain has moved from Sandoz to... Philip Morris International? (OK.
Thanks to Pharmalot's Ed Silverman, for pointing out the new website, Big Pharma Real People (click here to access and here for the site's mission statement). There is a need for the public to understand that the industry is made up of many altruistic, smart and compassionate people---even if some...
Sadly, this year will bring bad news, in the form of pink slips, for thousands of U.S. workers in a number of industries, as The Guardian recently reported (Click here for a sobering update). BMS leads the pharma pack just now.
In case any of you missed it, the Wall Street Journal just published a moving piece (click here to read) on pharma layoffs and their impact on the individual, in particular the chemists behind the small molecule drug. The article examines layoffs at Ann Arbor, Mich.